
UNC Health Southeastern Taps Transact + CBORD to Launch Mobile Meal Ordering
Transact + CBORD is bringing personalized, tech-powered nutrition to the bedside—helping UNC Health Southeastern make hospital stays more empowering and connected.
Share
The CBORD® Patient App connects directly to UNC Health Southeastern's nutrition system, enabling real-time access to personalized meal choices based on each patient's dietary needs. The app displays only foods appropriate to the patient's clinical diet and provides guidance for those on nutrient-controlled diets (e.g., fluid, carbohydrate, protein), automatically limiting selections that exceed allowable thresholds.
'I am extremely proud of the effort our team has put forth to ensure that our patients, family members and staff have a more convenient, accurate and efficient way to order food,' said UNC Health Southeastern VP and Chief Engagement Officer Patrick Ebri, PhD. 'It is indeed a game changer.'
The pilot program is currently live in the Women's Health Services Unit, with plans to expand to additional hospital units later this year.
'We're redefining what patient-centered care looks like — starting with the menu,' said Arun Ahuja, SVP & GM - Healthcare & Corporate at Transact + CBORD. 'Together with UNC Health Southeastern, we're making hospital stays more personalized and empowering through technology.'
For more information on the CBORD Patient App, visit: https://www.cbord.com/hc-wb-empowering-patients-self-order-app/?source=blog-healthcare.
About UNC Health Southeastern
In addition to offering services you'd expect from a community healthcare system, UNC Health Southeastern provides a number of specialized services that are unique to our system and not available anywhere else in the region. The nonprofit system, which is part of UNC Health, offers a combination of acute care, intensive care and psychiatric services to more than 13,000 inpatients and 50,000 emergency patients annually. It is our mission to provide exceptional care for our diverse region; offer the highest quality standards in a safe environment; and provide compassionate care provided by a committed team. At UNC Health Southeastern, together, we will improve the health and well-being of the region we serve. We are Here for you. Here for good. To learn more, visit UNCHealthSE.org.
About CBORD
The CBORD Group, Inc. (CBORD), a business unit of Roper Technologies (Nasdaq: ROP), is a leading provider of food and nutrition service management software, integrated security solutions, campus card and cashless systems, and commerce platforms for healthcare, senior living, higher education, and business campuses. With over 10,000 organizations using CBORD solutions globally, CBORD is committed to delivering innovative and comprehensive technology solutions that enhance the daily lives of patients, residents, students, staff, and administrators.
About Transact Campus
Transact Campus, a business unit of Roper Technologies (Nasdaq: ROP), is a leader in innovative payment, campus ID, and commerce solutions for a connected campus. Transact's highly configurable, mobile-centric campus technology ecosystem simplifies the user experience across the full spectrum of campus life. Transact's offerings include integrated solutions for tuition and other student expense payments, multi-purpose campus IDs, and campus commerce. For more information, visit www.transactcampus.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 14, the company delivered positive clinical data from the Phase 3 PaTHway Trial, which affirmed that TransCon PTH (palopegteriparatide) offered benefits to adults with hypoparathyroidism. A close-up of a pharmacist in a gleaming white labcoat holding a vial of biopharmaceuticals. Hypoparathyroidism is an endocrine disorder characterized by a deficiency of parathyroid hormone, which regulates the balance of calcium and phosphate. Serious side effects from the illness can include cognitive decline, renal problems, and neuromuscular irritability. The new three-year data for the Phase 3 PaTHway Trial, presented at the ENDO 2025 conference, showed improvements in biochemical markers, kidney function, and quality of life. Kidney function was maintained through week 156, as the mean glomerular filtration rate (eGFR) increased by 8.76 mL/min/1.73 m². No new safety concerns emerged during the trial phase, as the treatment was well-tolerated. 'These responses, including normalization of skeletal dynamics with significant and clinically meaningful improvements in kidney function, demonstrate the long-term benefits of this treatment option for the vast majority of adults with hypoparathyroidism,' said Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops new therapies to address unmet medical needs using the innovative TransCon technology platform. It focuses on rare endocrine diseases and oncology, with the goal of creating best-in-class treatments. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.